Presentation is loading. Please wait.

Presentation is loading. Please wait.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned  Joe Y. Chang, MD, PhD, Andrea Bezjak,

Published byIsabel Freeman Modified over 5 years ago

Similar presentations

Presentation on theme: "Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned  Joe Y. Chang, MD, PhD, Andrea Bezjak,"— Presentation transcript:

1 Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned  Joe Y. Chang, MD, PhD, Andrea Bezjak, MD, Françoise Mornex  Journal of Thoracic Oncology  Volume 10, Issue 4, Pages (April 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Recommended definition of central lesion: a tumor within 2 cm in all directions of any mediastinal critical structure, including the bronchial tree, esophagus, heart, brachial plexus, major vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Treatment plans and dose-volume histograms illustrate differences in doses to the mean PTV when doses are prescribed (Rx) to the 60%, 80%, and 100% isodose lines. PTV, planning target volume. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Beam-angle-optimized SABR plans for delivering 50 Gy in four fractions while keeping target coverage and avoiding overdoses to nearby critical structures for tumors in four locations: near the brachial plexus (A); near the major vessels (B); near the bronchial tree, esophagus and spinal cord (C); and near the esophagus and heart (D). Color wash dose distributions are shown with corresponding scales. The gray area inside the high-dose region indicates where the dose was higher than the scale maximum (6238 cGy). BP, brachial plexus; PV, pulmonary vessel; BT, bronchial tree; E, esophagus; SC, spinal cord; A, aorta; H, heart; GTV, gross tumor volume; SABR, stereotactic ablative radiotherapy. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned  Joe Y. Chang, MD, PhD, Andrea Bezjak,"

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Evaluation of the AAA Treatment Planning Algorithm for SBRT Lung Treatment: Comparison with Monte Carlo and Homogeneous Pencil Beam Dose Calculations 

Evaluation of the AAA Treatment Planning Algorithm for SBRT Lung Treatment: Comparison with Monte Carlo and Homogeneous Pencil Beam Dose Calculations 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Radiotherapeutic Management of Non–Small Cell Lung Cancer in the Minimal Resource Setting  Danielle Rodin, MD, Surbhi Grover, MD, MPH, Melody J. Xu, MD,

Radiotherapeutic Management of Non–Small Cell Lung Cancer in the Minimal Resource Setting  Danielle Rodin, MD, Surbhi Grover, MD, MPH, Melody J. Xu, MD,
Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe  Michelle C. Salazar, MD, Joshua E. Rosen, BASc,

Adjuvant Chemotherapy for T3 Non–Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe  Michelle C. Salazar, MD, Joshua E. Rosen, BASc,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined- Modality Treatment of Malignant Pleural Mesothelioma  Alexander Chi,

Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined- Modality Treatment of Malignant Pleural Mesothelioma  Alexander Chi,
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Postoperative Proton Therapy in the Management of Stage III Thymoma

Postoperative Proton Therapy in the Management of Stage III Thymoma
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer  Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,
Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy  Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy  Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,
Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review  Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,

Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review  Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,
Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J
Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer  Erik Roelofs,

Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer  Erik Roelofs,
The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer  Ramón Rami-Porta, MD, FETCS,

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer  Ramón Rami-Porta, MD, FETCS,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments  Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments  Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Similar presentations

Ads by Google